<?xml version="1.0" encoding="UTF-8"?>
<ref id="CIT0014">
 <mixed-citation publication-type="journal">
  <person-group person-group-type="author">
   <name name-style="western">
    <surname>Koschmieder</surname>
    <given-names>S.</given-names>
   </name>, 
   <name name-style="western">
    <surname>Jost</surname>
    <given-names>E.</given-names>
   </name>, 
   <name name-style="western">
    <surname>Cornelissen</surname>
    <given-names>C.</given-names>
   </name>, 
   <name name-style="western">
    <surname>Müller</surname>
    <given-names>T.</given-names>
   </name>, 
   <name name-style="western">
    <surname>Schulze‐Hagen</surname>
    <given-names>M.</given-names>
   </name>, 
   <name name-style="western">
    <surname>Bickenbach</surname>
    <given-names>J.</given-names>
   </name>, 
   <name name-style="western">
    <surname>Marx</surname>
    <given-names>G.</given-names>
   </name>, 
   <name name-style="western">
    <surname>Kleines</surname>
    <given-names>M.</given-names>
   </name>, 
   <name name-style="western">
    <surname>Marx</surname>
    <given-names>N.</given-names>
   </name>, 
   <name name-style="western">
    <surname>Brümmendorf</surname>
    <given-names>T. H.</given-names>
   </name>, &amp; 
   <name name-style="western">
    <surname>Dreher</surname>
    <given-names>M.</given-names>
   </name>
  </person-group> (
  <year>2020</year>). 
  <article-title>Favorable COVID-19 course despite significant comorbidities in a ruxolitinib-treated patient with primary myelo–brosis</article-title>. 
  <source>
   <italic toggle="yes">European Journal of Haematology</italic>
  </source>, (
  <issue>5</issue>), 
  <fpage>655</fpage>–
  <lpage>658</lpage>. 
  <pub-id pub-id-type="doi">10.1111/ejh.13480</pub-id>
  <pub-id pub-id-type="pmid">32593209</pub-id>
 </mixed-citation>
</ref>
